NAMPT is a CYCLOPS and druggable essential gene in −7/del(7q) myeloid malignancies. (A) Spearman correlation between relative NAMPT CN and NAMPT mRNA expression in 58 myeloid cancer cell lines based on CCLE relative CN data and expression data downloaded from DepMap portal. (B) Comparison of NAMPT Chronos scores (DepMap) between cell lines expressing higher (top 25% [n = 223]) and lower (bottom 25% [n = 278]) NAMPT mRNA (CCLE). (C) NAMPT mRNA (CCLE) levels in solid (n = 1231) vs hematopoietic (n = 219, myeloid and lymphoid) cancer cell lines. One-way analysis of variance (ANOVA) with Dunnett correction for multiple comparison tests was performed for statistical analysis. (D) SNP array data (left) summarized in a pie chart (right) from 27 −7/del(7q) patients. Of 27 −7/del(7q) patients, 22 (∼81%) were NAMPT haploinsufficient. (E) Comparison of NAMPT mRNA expression (z score RPKM) of TCGA patients with AML with normal karyotype (n = 87) vs −7/del(7q) patients haploinsufficient for NAMPT (n = 21). An unpaired 2-tailed t test was performed for statistical analysis. The results shown here are based on data generated by the TCGA research network. CN, copy number; RPKM, reads per kilobase per million mapped reads; TPM, transcripts per million.